Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/27/19
End: 03/31/20
Due: 03/31/21
Phase: N/A
Priority: Normal
Start: 10/14/20
End: 06/02/22
Due: 06/02/23
Phase: N/A
Priority: Normal
Start: 03/08/24
End: 11/30/25
Due: 11/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate LSALT Peptide | NCT03772678 | Arch Biopartners Inc. | user2@example.com | None | 2019-06-27 | 2020-03-31 | 2021-03-31 | - | - | 2025-07-14 |
| LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) | NCT04402957 | Arch Biopartners Inc. | user2@example.com | None | 2020-10-14 | 2022-06-02 | 2023-06-02 | - | - | 2025-07-14 |
| LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery | NCT05879432 | Arch Biopartners Inc. | user2@example.com | None | 2024-03-08 | 2025-11-30 | 2026-11-30 | - | - | 2025-07-14 |